Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
News
FDA Approves First Drug for The Prevention of Acute Graft Versus Host Disease
The Food and Drug Administration (FDA) recently approved abatacept (Orencia), in combination with certain immunosuppressants, for the prevention of ac…
News
FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse
The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectabl…
News
FDA Approves the First Interferon for Adults With Polycythemia Vera
This is the first medication approved for PV that patients can take regardless of their treatment history, meaning it can be used to treat this rare f…
News
FDA Approves Isatuximab for Relapsed/Refractory Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved isatuximab (Sarclisa) in combination with carfilzomib and dexamethasone to treat adult patients w…
Research
FDA Approves Vyxeos for Secondary Acute Myeloid Leukemia in Children
DUBLIN, March 30, 2021 - Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced that the U.S. Food and Drug Administration (FDA) approved a revised label f…
News
FDA Approval of New CAR T-Cell Therapy Further Solidifies Immunotherapy as a Mainstay in Cancer Treatment
The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR T-cell treatment for adult patients with certain forms of relapsed/r…
News
FDA Approval: Treatment Advance for Patients with Rare Blood Cell Disorder
On January 15, the U.S. Food and Drug Administration (FDA) announced approval of daratumumab plus hyaluronidase (Darzalex Faspro®) for adults with new…
News
FDA APPROVAL: TREATMENT ADVANCE FOR PATIENTS WITH MULTIPLE MYELOMA
The U.S. Food and Drug Administration (FDA) today announced approval of selinexor (Xpovio®) for adults with multiple myeloma who have had at least one…
